About Tessa Therapeutics
Tessa Therapeutics is a clinical-stage immunotherapy company focused on the development of autologous and off-the-shelf, allogeneic therapies for cancer patients.
Our Virus-Specific T cell (VST) platform harnesses the body’s potent anti-viral immune response and has shown compelling results in the treatment of solid tumors.
We are building a portfolio of innovative, next-generation therapies which combine the qualities of VSTs with other immuno-oncology technologies.
Our robust operational and supply chain capabilities enable us to successfully deliver T cell therapy treatments to a large patient pool worldwide. Together with our academic, clinical, and commercial research partners, we have created a fully-integrated approach to the treatment of cancer with immunotherapy.
The immunosuppressive tumor microenvironment presents significant obstacles to the treatment of solid tumors with immunotherapy. Our Virus-Specific T cell (VST) technology overcomes these barriers and has shown promising clinical success.
We have a rapidly growing pipeline of autologous and allogenic therapies targeting multiple cancer indications. These innovative, next-generation therapies combine the qualities of VSTs with other immuno-oncology technologies.
We are committed to working towards a vision of a world without untreatable cancers. We are constantly advancing our understanding of the body’s immune system to design next-generation VST therapies which demonstrate persistence, durability, and tumor penetration with minimal side effects for patients.
Tessa on Twitter
January is #CervicalCancerAwarenessMonth. #HPV infection is strongly associated with #CervicalCancer. Tessa is working hard to develop #VST #CellularImmunotherapy to treat cervical cancer patients. More on Tessa's ongoing trial for HPV-associated cancers: https://t.co/5K2q227Hkt https://t.co/pM2YEzWr0T
We are delighted to announce that Dr. George W. Sledge, Jr. ( @GeorgeSledge51), M.D., Professor and Chief of Medical Oncology at @StanfordMed, will join Tessa’s Board of Directors as an independent director, effective 2 January 2019. #TopOfTessa #Immunotherapy https://t.co/ofeQ43hLDB
Tessa’s Media Channel
CNBC Anchor, Nancy Hungerford speaks with Tessa’s CFO, Desmond Lim about the Company’s future plans and the promise of Virus-Specific T Cell (VST) cancer immunotherapy.